SER-109 Improves Disease-Specific Quality Of Life For Patients With Recurrent Clostridioides Difficile Infection, Data Indicate

Healio (3/3, Burba) reported “use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to” a “secondary...